Physician profile
Mohit Gupta
NPI 1831395441
$6,290.66
in general payments reported to CMS, 2019-2025
35 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,239 · 2020: $446 · 2021: $723 · 2022: $477 · 2023: $566 · 2024: $1,693 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,405.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $727.69 | 2023-2025 | Assure Wcd |
| Medtronic, INC. | $488.32 | 2022-2025 | Venaseal, Linq II |
| Esperion Therapeutics, INC. | $421.02 | 2021-2024 | Nexletol |
| Ge Healthcare | $364.06 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $340.19 | 2019-2024 | Xarelto |
| Abbott Laboratories | $329.08 | 2021-2024 | Cardiomems |
| Boston Scientific Corporation | $295.92 | 2020-2023 | Varithena Administration Pack, Bodyguardian |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.76 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $263.58 | 2020-2025 | Wainua, Farxiga |
| Abiomed | $256.26 | 2024-2025 | Impella |
| Amgen INC. | $251.37 | 2019-2024 | Repatha |
| Pfizer INC. | $235.25 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $207.96 | 2020-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $201.88 | 2023-2025 | Camzyos |
| Biocompatibles, INC. | $191.53 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $185.32 | 2019-2021 | |
| Atricure, INC. | $170.24 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Alnylam Pharmaceuticals INC. | $168.20 | 2024-2025 | Onpattro |
| Penumbra, INC. | $153.42 | 2025 | Penumbra System |
| Novo Nordisk INC | $100.80 | 2024 | |
| Novartis Pharmaceuticals Corporation | $92.05 | 2019-2025 | |
| Heartflow, INC. | $81.12 | 2022-2024 | Ffrct |
| Btg International INC. | $78.96 | 2019 | |
| Venclose INC. | $76.44 | 2020 | |
| Impulse Dynamics (USA) INC. | $69.21 | 2022 | |
| Biosense Webster, INC. | $54.32 | 2024 | Nuvision Ice Catheter |
| Medtronic Vascular, INC. | $35.38 | 2019 | |
| United Therapeutics Corporation | $32.82 | 2025 | Tyvaso |
| Cashflow Solutions, LLC | $31.95 | 2025 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
| Daiichi Sankyo INC. | $24.02 | 2024 | Injectafer |
| Lundbeck LLC | $22.86 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $20.97 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $19.82 | 2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $14.92 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohit Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.